Partnering with Us

The CompuFlo^® system’s value proposition to health and medical companies is highly tangible and quantifiable, empowering such things as patent life extensions on leading injectable drugs; providing ‘painless’ marketing differentiation for intramuscular and subcutaneous injectable treatments; and perhaps, most important, helping to drive greater patient compliance, thus improving quality of life for patients requiring injectable drugs while promoting greater revenue growth for the companies that produce them. 

Milestone is currently seeking to establish strategic collaborations with companies interested in exploring opportunities to develop new disruptive drug delivery technologies that will enable them to raise the barriers to market entry and differentiate their drug products from those delivered by otherwise conventional means. 

Milestone anticipates that any application for a device developed utilizing the CompuFlo system will require 510(k) approval from the FDA, which should reduce development cost and time to market.

To explore partnering opportunities, please contact us at mike@plrinvest.com.